美女内射毛片在线看免费人动物 I 4438x在线观看 I 日美女的逼逼 I 午夜宅男在线 I snh48国产大片永久 I 成年人小视频 I 国产在线播放网址 I 日韩a级片免费观看 I 麻豆综合在线 I 国产精品泄火熟女 I 伊人综合久久 I 亚洲精品免费一区亚洲精品免费精品一区 I 国产清纯美女白浆在线播放 I 高清|国产|在线视频在线观看免费 I 久久天天躁狠狠躁夜夜av不卡 I 日韩成人无码毛片一区二区 I 国产精品久久影院 I 丰满的人妻hd高清日本 I 女厕偷窥一区二区三区 I 又粗又长又硬义又黄又爽 I 在线观看吴梦梦 I 国产精品日韩一区二区 I 国产福利第一视频在线播放 I 后入内射欧美99二区视频 I 上司人妻互换hd无码 I 韩国成年人网站 I 国内高清久久久久久 I 国产黄a三级三级三级看三级黑人 I 一区二区免费视频 I av福利免费 I 火箭视频在线观看精品 I 国产一区国产二区国产三区 I 国产经典 欧美精品 I 亚洲伦理在线精品 I 韩国理论在线视频

Cell Line Name：

SLC34A2-ROS1/BaF3

Host Cell:

Ba/F3

Application:

Anti-proliferation assay and PD assay

Freeze Medium:

90% FBS+10% DMSO

Complete Culture Medium:

RPMI-1640+10%FBS

Mycoplasma Status:

Negative

Approximately 2% of lung tumors harbor ROS1 fusions (Bergethon et al. 2012). Like ALK fusions, ROS1 fusions are more commonly found in light smokers (<10 pack years) and/or never-smokers. ROS1 fusions are also associated with younger age and adenocarcinomas (Bergethon et al. 2012).

In preclinical models, ROS1 fusions are associated with sensitivity to tyrosine kinase inhibitors that have 'off-target' activity against ROS1, such as crizotinib (Bergethon et al. 2012; Davies et al. 2012). In addition, two patients—a previously treated metastatic NSCLC patient and a 65-year-old never smoker NSCLC patient—with tumors harboring ROS1 fusions have had partial responses to crizotinib (Bergethon et al. 2012; Davies et al. 2012). In an expansion cohort of a phase I study, 50 patients with ROS1-positive NSCLC demonstrated a 72% response rate and 19.2-month median progression-free survival interval when treated with crizotinib (Ou et al. 2013; Shaw et al. 2014). In a European case study, 32 ROS1-positive NSCLC cases treated with crizotinib were retrospectively reviewed, and an 80% response rate and a 9.1-month median progression-free survival interval was calculated in this cohort (Mazières et al. 2015).

Several different ROS1 rearrangements have been described in NSCLC. These include SLC34A2-ROS1, CD74-ROS1, EZR-ROS1, TPM3-ROS1, and SDC4-ROS1 (Figure 1; Davies et al. 2012; Rikova et al. 2007; Takeuchi et al. 2012). Clinically, the presence of a ROS1 rearrangement is detected by fluorescence in situ hybridization (FISH) with a ROS1 breakapart probe. FISH testing is not able to discern which particular ROS1 fusion is found in a clinical sample.

ROS1 rearrangements are non-overlapping with other oncogenic mutations found in NSCLC (e.g., EGFR mutations, KRAS mutations, ALK fusions, etc.; Bergethon et al. 2012).

1. WB of SLC34A2-ROS1 expression

2.Sanger Sequencing of SLC34A2-ROS1 Fusion

2. Anti-proliferation assay

Figure 3. Anti-proliferation assay of two reference compounds on the SLC34A2-ROS1/BaF3 Stable Cell Line.